Faeth Therapeutics, Inc. Proceeds from Stock Options Exercised
Faeth Therapeutics, Inc. (FTH) reported Proceeds from Stock Options Exercised of $1.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-04
- Faeth Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $98.00K.
- Faeth Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $1.03M.
- Faeth Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-06-30 was $0.00.
- Faeth Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-03-31 was $0.00.
- Faeth Therapeutics, Inc. proceeds from stock options exercised for fiscal 2025 was $2.00K.
- Faeth Therapeutics, Inc. proceeds from stock options exercised for fiscal 2024 was $0.00.
- Faeth Therapeutics, Inc. proceeds from stock options exercised for fiscal 2022 was $238.00K, a 720.69% increase from fiscal 2021.
- Faeth Therapeutics, Inc. proceeds from stock options exercised for fiscal 2021 was $29.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $1.13M 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $2.00K 10-K · filed 2026-03-30 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $238.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $238.00K 10-Q · filed 2023-11-07 | $266.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $238.00K 10-Q · filed 2023-08-03 | $266.00K derived: sum of 3 quarters · filed 2023-08-03 | $266.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $238.00K 10-Q · filed 2023-05-09 | $266.00K derived: sum of 2 quarters · filed 2023-05-09 | $266.00K derived: sum of 3 quarters · filed 2023-05-09 | $266.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $28.00K derived: sum of 2 quarters · filed 2023-03-29 | $28.00K derived: sum of 3 quarters · filed 2023-03-29 | $29.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $1.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |